In normal thyroid cells, the TSH-adenylate cyclase system plays a pivotal role in controlling growth and differentiation. However, the role of this system in the growth of thyroid carcinoma is not well understood. To investigate this subject, we have established four new human thyroid carcinoma cell lines, designated BHP 2-7, 7-13, 10 -3, and 18 -21, from different patients. Northern gel analysis revealed that all of these cell lines expressed Pax-8 messenger ribonucleic acid; additionally, only BHP 18 -21 cells expressed TTF-1 messenger ribonucleic acid. These cells were treated with various concentrations of 8-bromo-cAMP, forskolin, TSH, and adrenergic receptor agonist (norepinephrine, epinephrine, and isoproterenol). 3 H]CGP-12177, a specific ␤-adrenergic agonist, revealed that these new thyroid carcinoma cells had ␤-adrenergic receptors. These results indicate that cAMP inhibits the growth of some human thyroid carcinoma cells, and that cAMP production is regulated through ␤-adrenergic receptor-mediated pathways, but not through TSH receptor-mediated pathways. (J Clin Endocrinol Metab 82: 2633-2638, 1997 
I
T IS WELL known that TSH promotes the growth and differentiation of normal thyroid cells by activation of adenylate cyclase (1) (2) (3) . In contrast, the role of the TSHadenylate cyclase system in controlling the growth of thyroid carcinoma is still controversial (4 -9) . It is important to clarify the participation of this system in the growth of thyroid carcinoma.
There are reports showing that cAMP may act as a growth inhibitor, but not stimulator, in some human thyroid carcinoma cell lines (4 -7) . In these reports, the administration of a cAMP analog inhibited the growth of carcinoma cells, although TSH did not affect cAMP production. These results suggest that the role of the adenylate cyclase system in thyroid carcinoma cells might be different from that of normal thyroid cells, and that adenylate cyclase is activated by a substance other than TSH.
Recently, Endo et al. (10) established a malignantly transformed rat thyroid cell line and showed that a ␤-adrenergic agonist inhibited the growth of this cell. Additionally, Lin et al. (11) reported overexpression of the ␤ 2 -adrenergic receptor messenger ribonucleic acid (mRNA) in human thyroid carcinoma tissues obtained at surgery. These results suggest the possibility that the activation of adenylate cyclase through the ␤-adrenergic receptor regulates the growth of human thyroid carcinoma cells.
To further investigate this subject, we have established four new human thyroid carcinoma cell lines. In this paper, we report that some human thyroid carcinoma cell lines express the ␤-adrenergic receptor and that cAMP induced through the stimulation of ␤-adrenergic receptor inhibited the growth of these cell lines.
Materials and Methods
Materials the cell lines was described previously (12) . Briefly, these tissues were minced and digested with collagenase (2 mg/mL) and trypsin (50 mg/ mL) in RPMI 1640 medium at room temperature for 60 -90 min. Cells were cultured in RPMI 1640 medium supplemented with 10% FBS in flasks for 3-7 days. To establish cloned cell lines, cells were reseeded in 96-well plates after limiting dilution and cultured.
Northern gel analysis
Total RNA was prepared by the acid-guanidinium thiocyanate phenol chloroform method (13) . Twenty micrograms of total RNA were denatured and electrophoresed in a 1% agarose gel containing 6.0% formaldehyde and 20 mmol/L morpholinepropane sulfonic acid (MOPS) buffer. RNA was then blotted onto nitrocellulose membrane with 20 ϫ SSC (standard saline citrate). After prehybridization for 4 h at 42 C in a solution containing 50% deionized formamide, 5 ϫ SSC, 50 mmol/L sodium phosphate (pH 6.7), 40 mg/mL denatured salmon sperm DNA, and 4 ϫ Denhardt's solution (50 ϫ Denhardt's is 10 g/L polyvinylpyrrolidone, 10 g/L Ficoll, and 10 g/L BSA), the membranes were hybridized to 32 P-labeled complementary DNA (cDNA) overnight at 42 C. Blots were washed in 2 ϫ SSC-0.1% SDS three times at room temperature for 10 min and then in 0.1 ϫ SSC-0.1% SDS three times at 50 C for 20 min. Filters were exposed to Kodak XAR-5 film at Ϫ70 C using a fluorescent intensifying screen.
The cDNAs used in these studies were as follows: TTF-1 cDNA ligated into pBluescript was provided by Dr. James Fagin (University of Cincinnati, Cincinnati, OH). We used the HindIII-ApaI fragment, which contains 1-331 bp of TTF-1 cDNA (14) . Pax-8 cDNA ligated into pGEM-T was provided by Dr. Hisao Seo (Nagoya University, Nagoya, Japan). We used the XhoI-PstI fragment, which contains 855-1156 bp Pax-8 cDNA (15) . The human thyrogloblin (Tg) cDNA was provided by American Type Culture Collection (ATCC 57736, Rockville, MD). The human thyroid peroxidase and TSH-R cDNAs were provided by Dr. Basil Rapoport (University of California-San Francisco) (16, 17) . The sodium/ iodide symporter cDNA was provided by Dr. Nancy Carrasco (Albert Einstein College of Medicine, New York, NY) (18) . The probes were labeled with [␣-32 P]deoxy-CTP using a multiple DNA-labeling system (Amersham International, Aylesbury, UK) to a specific activity of approximately 5-10 ϫ 10 8 cpm/g DNA.
Cell number measurement
Cells were seeded at a density of 5 ϫ 10 3 cells/well of 48-well tissue culture plates in 0.5 mL RPMI 1640 medium supplemented with 10% FBS with and without the indicated materials. The culture medium was changed every 3 days. After culture for 6 days, the cells were detached from the plate by incubation with 500 L PBS containing 1 mg/mL trypsin and 1 mmol/L ethylenediamine tetraacetate. Cell number was determined by counting in a hemocytometer.
[ 3 
H]thymidine incorporation
The cells grown to confluence in 24-well tissue culture plates were treated with the indicated concentrations of test substances in 1 mL of RPMI-1640 medium supplemented with 10% FBS for 24 h. Subsequently, cells were incubated with 0.5 Ci [
3 H]thymidine in each well for 4 h. Cells were then washed with 1 mL ice-cold PBS twice and harvested with 1 mL PBS containing 1 mg/mL trypsin and 1 mmol/L ethylenediamine tetraacetate and sonicated. Trichloroacetic acid (10%)-precipitable radioactivity was determined by liquid scintillation counting.
Assay of cAMP formation
The assay of cAMP response was performed as previously reported (19) . In brief, the cells grown to 90% confluence in 24-well plates were washed with Hanks' Balanced Salt Solution (HBSS) with 20 mmol/L HEPES (pH 7.4) twice. The cells were then incubated with the indicated substances in 300 L HBSS with 20 mmol/L HEPES (pH 7.4) containing 1% (wt/vol) BSA and 0.5 mmol/L 1-methyl-3-isobutylxanthine at 37 C for 1 h. After incubation, the assay media were collected for cAMP measurement using a commercially available RIA kit (Incstar Co., Stillwater, MN). 
Binding of [ 3 H]CGP-12177 to BHP cells

Statistical analysis
Experiments were performed in triplicate wells, and all data are presented as the mean Ϯ sd. All results are representative of at least two independent experiments. Statistical analysis was performed by oneway ANOVA. Statistical significance was set at P Ͻ 0.05. Scheffe's F post-hoc method was used for detecting significant differences between group means. However, mRNAs of thyroglobulin, TSH receptor, thyroid peroxidase, and sodium/iodide symporter were not detected in these thyroid carcinoma cell lines by Northern blot analysis (data not shown). (Fig. 4) . In NP and BHP 17-10 cells, isoproterenol, epinephrine, and norepinephrine did not affect [ 3 H]thymidine incorporation even at a concentration of 10 mol/L.
Results
Characterization of new thyroid carcinoma cells
Effects on cell number
Forskolin (0.1 mol/L), epinephrine (1 mol/L), and isoproterenol (0.1 mol/L) significantly decreased the numbers of BHP 2-7, 7-13, 10 -3, and 18 -21 cells compared with the control values (Table 1 ). In contrast, these treatments did not significantly change the growth of NP and BHP 17-10 cells. TSH (1 mU/mL) did not influence the growth of all cell lines examined.
cAMP production by thyroid carcinoma cell lines
TSH (1 mU/mL) did not stimulate cAMP production by any of the cell lines examined (Table 2) . Conversely, forskolin (1 mol/L) remarkably increased the production of cAMP by 3.3-to 6.7-fold of the control value in every cell line examined. Furthermore, the addition of 1 ng/mL cholera toxin induced the accumulation of cAMP in all thyroid carcinoma cells. We found that isoproterenol (0.1 mol/L) and epinephrine (1 mol/L) stimulated cAMP production only in the BHP 2-7, 7-13, 10 -3, and 18 -21 cell lines, by at least 5-fold over the control value. In contrast, isoproterenol (0.1 mol/L) and epinephrine (1 mol/L) did not significantly stimulate cAMP production by NP and BHP 17-10 cells. The addition of 1 mmol/L isoproterenol significantly increased cAMP production by NP cells, although its stimulative effect was less than that on the BHP 2-7, 7-13, 10 -3, and 18 -21 cell lines. Figure 5 shows the binding of 
Binding of [ 3 H]CGP-12177
Discussion
In the present study, we established four new human thyroid carcinoma cell lines, designated BHP 2-7, 7-13, 10 -3, and 18 -21, from different patients. All of these cells express Pax-8 mRNA, the presence of which is restricted to thyroid and kidney (21) . Additionally, BHP 18 -21 cells also express TTF-1 mRNA, the presence of which is restricted to thyroid and lung (22) . TTF-1 and Pax-8 are transcription factors, contributing to the expression of thyroid-specific proteins such as thyroglobulin or thyroid peroxidase (23) . The presence of Pax-8 and/or TTF-1 mRNA indicate that these cells originate from the thyroid follicular cell. However, none of these cells expresses the mRNAs of TSH receptor, thyroid peroxidase, thyroglobulin, or sodium/iodide symporter (data not shown). In agreement with previous studies, these results suggest a certain degree of dedifferentiation of these new thyroid carcinoma cells (24) . Consistent with our finding, Fabbro et al. reported that Pax-8 mRNA expression was always detected in papillary carcinoma tissues, although thyroglobulin or thyroid peroxidase mRNAs were not always expressed (23) .
Controversial results have been reported on the effect of cAMP on thyroid carcinoma growth. Kimura et al. (5) showed that 8-bromo-cAMP reduces [ 3 H]thymidine incorporation into NP and WRO thyroid carcinoma cells. In contrast, Hoelting et al. (8) reported that dibutryl cAMP did not affect the growth of FTC 133 human follicular thyroid carcinoma cells. This discrepancy might stem from the specific cell lines and cAMP analog used. In this study, we examined the effects of 8-bromo-cAMP on the growth of six human thyroid carcinoma cell lines, including four new cell lines. The present data demonstrate that the growth inhibitory effect of 8-bromo-cAMP is considerably higher on newly established BHP thyroid carcinoma cell lines than on NP and BHP 17-10 thyroid carcinoma cells. The different potency of 8-bromocAMP on the growth inhibition is probably attributable to the differences in cAMP-dependent protein kinase isozymes in these cell lines (25) (26) (27) . It is noteworthy that all human thyroid carcinoma cell lines examined showed growth inhibition by 8-bromo-cAMP. In contrast, 8-bromo-cAMP significantly increased [ 3 H]thymidine incorporation by FRTL rat thyroid cells. These results suggest the possibility that the inhibition of growth by cAMP might be a characteristic of some human thyroid carcinomas.
The mechanism by which cAMP inhibits the growth of these human thyroid carcinoma cells is still unknown. ChoChung et al. reported the growth inhibitory effect of cAMP analogs on a broad spectrum of human cancer cell lines, including breast, colon, lung, and gastric carcinoma (25) (26) (27) . In these reports, they showed that the growth inhibition paralleled suppression of cellular protooncogene expression, such as c-myc and c-ras. The induction of protooncogene expression by cAMP needs to be compared in the new BHP and NP cells to further clarify the antiproliferative mechanism of cAMP on thyroid carcinoma cells.
In the second part of our study, we investigated a substance that may promote cAMP production in these thyroid carcinoma cells. As a first step, we examined the effect of TSH at various concentrations (1-1000 mU/L), but we could not show any stimulatory effect of TSH on all cell lines examined. In normal thyroid cells, binding of TSH to its receptor leads to stimulation of the G s protein ␣-subunit and subsequent activation of adenylate cyclase (28) . We showed that forskolin and cholera toxin significantly induced cAMP production by all carcinoma cell lines tested. These results indicate that the cause of impaired cAMP response to TSH is at the level of the receptor and not at the level of G s protein and adenylate cyclase. Northern blot analysis showed the loss of expression of TSH receptor mRNA. These results indicate that the TSH-adenylate cyclase system is no longer important for the regulation of growth of these human thyroid carcinoma cells.
In this study, we demonstrated that adrenergic receptor agonists stimulated cAMP production and mimicked the growth inhibitory effects of 8-bromo-cAMP on the new BHP thyroid carcinoma cells. The rank of potency of agonists was isoproterenol Ͼ epinephrine Ͼ Ͼ norepinephrine. These results suggest that the type of receptor expressed on the new BHP thyroid carcinoma cells is the ␤ 2 -type adrenergic receptor. Our finding is in agreement with a previous report of a malignantly transformed rat thyroid cell line (10) .
This study also demonstrated that the new BHP thyroid carcinoma cell lines, which expressed a high number of ␤-adrenergic receptors, are more sensitive to the growth inhibitory effects of cAMP. These results suggest the possibility that expression of ␤-adrenergic receptor functions to inhibit the growth of these thyroid carcinoma cells.
The mechanism by which ␤-adrenergic receptor expression is induced in these thyroid carcinomas cell lines is not known. Furthermore, the reason why the thyroid carcinoma cell lines, the growth of which is inhibited by a low concentration of cAMP, express more ␤-adrenergic receptors also remains to be elucidated. For such studies, the new BHP thyroid carcinoma cells should be a useful model.
In summary, we successfully established four new human thyroid carcinoma cell lines from different patients. Using these cell lines, we demonstrated that cAMP acts as a growth inhibitor in these cells. Moreover, we showed that cAMP production was stimulated via the ␤-adrenergic receptor, but not by the TSH receptor. Although the in vitro behavior of these thyroid carcinoma cell lines may not reflect that in vivo, it is noteworthy that the growth of some thyroid carcinoma cell lines was remarkably inhibited by ␤-adrenergic agonist. These in vitro observations suggest that the growth inhibition by ␤-adrenergic agonist may be characteristic of some human thyroid carcinomas.
